The Pharma Data

SEPTEMBER 28, 2021

The presentations included additional results from the RAINBOWFISH study, evaluating the efficacy and safety of Evrysdi® (risdiplam) in babies with pre-symptomatic spinal muscular atrophy (SMA) from birth to 6 weeks aged and data supporting the continued clinical investigation of gene therapy, SRP-9001, in Duchenne dystrophy (DMD).

Clinical Trials 52

Clinical Trials Protein Expression Therapies FDA 52

The Pharma Data

DECEMBER 3, 2020

Highlights from the Company’s presentations include: BUTTERFLY Observational Study – Baseline Analysis. A review of the study design for MONARCH, the Company’s ongoing Phase 1/2a study of STK-001 in children and adolescents with Dravet syndrome will be presented during a poster session by Linda Laux, M.D., Antiepileptic Drugs / 7B.

Clinical Trials 52

Clinical Trials Protein Expression Pharmacokinetics Trials 52

The Pharma Data

SEPTEMBER 2, 2020

Other data to be presented will show high treatment persistence and strong adherence for patients treated with OCREVUS compared to other DMTs in real-world settings. A full list of Roche presentations can be found at: [link]. Presentations at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting include: Medicine. Abstract Title.

Clinical Trials 52

Clinical Trials Disease Treatment Therapies 52

The Pharma Data

JANUARY 16, 2021

Etta Biotech”), to set up a high titer transient protein expression platform for high quality protein production using JS Bio’s transient transfection media. JS Bio becomes the exclusive cell culture supplier for Etta Biotech’s transient transfection high titer protein expression platform.

Protein Expression 52

Protein Expression Protein Production Production Drug Development 52

Drug Target Review

JANUARY 26, 2024

The level of human ACE2 protein produced by the cells was generally proportional to the number of ACE2 gene copies integrated into the mouse genome. Several of the mouse cell clones produced about 50 times more ACE2 than is normally present on mouse cells.

Production 114

Production DNA Virus Protein Expression 114

Drug Target Review

MARCH 15, 2024

Transposons preferentially integrate the gene of interest into active transcriptional sites, facilitating rapid cell line development and higher titers of the protein drug. Furthermore, adoption of automated and standardised cell counting and clone selection technologies can help optimise cell line development workflows.

Engineering 105

Engineering Molecular Biology Protein Expression Medical Schools 105

Broad Institute

SEPTEMBER 26, 2024

Preliminary western blot and immunofluorescence assays for protein expression reflected the presence of aged phenotypes, including decreased expression of Lap2β and H3K9me3, in hiPSC-astrocytes treated with the senescence cocktail.

Small Molecule 52

Small Molecule Protein Expression Disease Science 52

DrugBank

JULY 24, 2024

Additionally, while small molecules can target well-defined pockets on enzymes or receptors, targeting PPIs presents a unique challenge due to their flat, featureless interfaces and large interaction areas. Despite these challenges, the progress in PPI-modulating drugs is noteworthy.

Small Molecule 98

Small Molecule Drugs Clinical Trials Therapies 98

Broad Institute

SEPTEMBER 5, 2024

In recent years, increasingly sensitive mass spectrometers have paved the way for enormous progress: scientists are now able to detect and analyze nearly all proteins expressed in a sample, including ones present only in miniscule amounts. We’re also now able to do better and more reproducible protein quantitation, which is key.

Disease 85

Disease Protein Expression Engineering Treatment 85

Elrig

JUNE 13, 2024

The free-to-attend conference also includes poster presentations, networking sessions as well as a vendor exhibition, and offers travel bursary opportunities for early career professionals.

Science 52

Science Protein Expression Drugs International 52

Drug Target Review

MAY 22, 2024

Secondly, circRNAs can be engineered for more efficient protein expression by carefully selecting and optimising the IRES element, a sequence motif derived from viruses and used to initiate cap-independent translation from circRNA. What improvements in protein expression and durability have been demonstrated by the circVec 2.1

Therapies 59

Therapies RNA Protein Expression DNA 59

The Pharma Data

APRIL 8, 2021

Additional presentations on investigational programmes, including Alzheimer’s disease and Huntington’s disease, help advance scientific understanding of neurological disorders. Roche will present data from five studies from the EVRYSDI clinical development programme, which was designed to represent a broad spectrum of people living with SMA.

Clinical Trials 52

Clinical Trials Trials Disease Therapies 52

The Pharma Data

APRIL 26, 2022

Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick. No vaccine-related serious adverse events (SAEs) were observed.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

JUNE 7, 2023

Results will be presented on June 6 during an oral presentation (#9004) at the American Society of Clinical Oncology Annual Meeting (#ASCO23). 3,4,5 TROP2 is a protein expressed in more than 90% of NSCLC tumors. More than one million people are diagnosed with NSCLC at an advanced stage each year.

Trials 40

Trials Protein Expression Therapies Treatment 40

The Pharma Data

MARCH 8, 2021

This investigational multivalent protein subunit vaccine targets the outer surface protein A (OspA) of Borrelia, an established mechanism of action for a Lyme disease vaccine. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

The Pharma Data

AUGUST 16, 2021

The vaccine candidate, presently at a preclinical development stage, is a non-chemically modified mRNA, encoding the prefusion stabilized full-length spike protein of the SARS-CoV-2 virus, and formulated within Lipid Nanoparticles (LNPs).

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

APRIL 27, 2022

The data will be presented at an upcoming medical meeting. Breast cancer and HER2 expression Breast cancer is the most common cancer and is one of the leading causes of cancer-related deaths worldwide and in the US. The safety profile of Enhertu was consistent with previous clinical trials with no new safety concerns identified.

Therapies 52

Therapies Trials Protein Expression Treatment 52

The Pharma Data

SEPTEMBER 10, 2020

Findings will be presented at MSVirtual2020, the 8 th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS). Separate data from a U.S. This nerve cell damage can lead to disability in people with MS.

Treatment 52

Treatment Disease FDA Approval Clinical Trials 52

Broad Institute

OCTOBER 4, 2023

Related links Merkin Prize Inaugural Merkin Prize in Biomedical Technology awarded to Dr. As reported last year in ACS Chemical Biology , Wang’s lab developed a way to construct messenger-oligonucleotide conjugated RNAs with chemically modified tails, a strategy that reduced RNA degradation while increasing therapeutic protein expression in cells.

DNA 52

DNA RNA Science Protein Expression 52

The Pharma Data

JULY 21, 2021

This investigational multivalent protein subunit vaccine uses an established mechanism of action for a Lyme disease vaccine that targets the outer surface protein A (OspA) of Borrelia burgdorferi , the bacteria that cause Lyme disease. OspA is one of the most dominant surface proteins expressed by the bacteria when present in a tick.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Target Review

SEPTEMBER 10, 2024

For example, advances in media and feeds have contributed to higher cell protein expression by optimising nutrient availability and reducing accumulation of waste products within a culture. Novel vector design and synthetic promoters have been designed to maximise productivity and enhance gene expression stability.

Drug Development 64

Drug Development Clinical Supply Production FDA 64

Alta Sciences

APRIL 17, 2024

They work by binding to specific sequences of nucleotides present within the mRNA structure and can induce mechanisms that either decrease, restore, or modify protein expression. And since proteins are often linked to disease, there's huge potential to treat a broad range of diseases with this technology.

Drug Development 52

Drug Development Treatment FDA Approval Drugs 52

The Pharma Data

SEPTEMBER 8, 2020

Overviews of clinical trials and scientific rationale will be presented at MSVirtual2020, the 8th Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) and the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) from 11-13 September 2020.

Clinical Trials 52

Clinical Trials Trials Disease FDA Approval 52

The Pharma Data

AUGUST 9, 2021

We believe this highly sophisticated and specifically engineered ADC is fulfilling its promise to reshape the treatment of HER2-positive metastatic breast cancer, with the goal to move into earlier lines of treatment for HER2-positive breast cancer and many other HER2-expressing tumour types across our broad clinical trial programme.”.

Trials 52

Trials Treatment Clinical Trials Protein Expression 52

The Pharma Data

JANUARY 13, 2021

Patients with severe COVID-19 infection often present with acute severe inflammation and organ failure. The project aims to develop novel protein expression systems by leveraging recent advances in direct cell reprogramming to help improve the production of proteins which are not produced sufficiently well in existing expression systems.

Licensing 52

Licensing Licensing Clinical Trials Trials 52

The Anticancer Fund

SEPTEMBER 29, 2021

Please get in touch if you’re interested in discussing research based on the findings presented below ( info@anticancerfund.org ). Data from patients in the clinical trial showed decreased HER2 total protein expression and phosphorylation of AKT and S6 proteins in tumours.

Clinical Trials 40

Clinical Trials Drugs Trials Protein Expression 40

The Pharma Data

OCTOBER 28, 2020

Further detail from the first five patients will be presented at the Foundation for Angelman Syndrome Therapeutics (FAST) Global Summit in December 2020. In almost all cases of Angelman syndrome, the maternal UBE3A allele is either missing or mutated, resulting in limited to no protein expression. About Angelman Syndrome.

Protein Expression 40

Protein Expression Therapies Treatment Disease 40

The Pharma Data

JANUARY 15, 2021

Results from the DESTINY-Gastric01 trial were presented at the 2020 American Society of Clinical Oncology (ASCO) meeting and published in The New England Journal of Medicine. 3 HER2 is a tyrosine kinase receptor growth-promoting protein expressed on the surface of many types of tumors including breast, gastric, lung and colorectal cancer.

Treatment 52

Treatment Trials Disease Therapies 52

The Pharma Data

OCTOBER 26, 2020

Following the unauthorized download of all abstracts on the SITC website, Transgene is communicating the content of the late-breaking poster abstract that will be presented at the SITC 35th Anniversary Annual Meeting (SITC 2020), to be held virtually November 9-14, 2020. Key findings of the trial: .

Vaccine 40

Vaccine Trials Treatment Virus 40

Conversations in Drug Development Trends

APRIL 7, 2025

Solid tumors present a significant challenge to clinical research due to their complex and heterogeneous nature. However, the emergence of precision medicine is revolutionizing the way we approach these tumors, offering new hope and innovative solutions.

40

40